Sequent Historical Balance Sheet

SEQUENT Stock

199.27 1.09 0.55%

Trend analysis of Sequent Scientific Limited balance sheet accounts such as Total Stockholder Equity of 4.5 B, Property Plant And Equipment Net of 2.9 B, Net Debt of 2.8 B or Cash of 354.1 M provides information on Sequent Scientific's total assets, liabilities, and equity, which is the actual value of Sequent Scientific to its prevalent stockholders. By breaking down trends over time using Sequent Scientific balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Sequent Scientific latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sequent Scientific is a good buy for the upcoming year.

Sequent Scientific Inventory

3.64 Billion

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sequent Scientific Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

About Sequent Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Sequent Scientific at a specified time, usually calculated after every quarter, six months, or one year. Sequent Scientific Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Sequent Scientific and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Sequent currently owns. An asset can also be divided into two categories, current and non-current.

Sequent Scientific Balance Sheet Chart

At this time, Sequent Scientific's Other Current Liabilities is comparatively stable compared to the past year. Inventory is likely to gain to about 3.6 B in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.8 B in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Retained Earnings

Add Fundamental

Total Assets

Total assets refers to the total amount of Sequent Scientific assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sequent Scientific books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most accounts from Sequent Scientific's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Sequent Scientific current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sequent Scientific Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	3.6B	4.4B	4.9B	3.1B
Total Assets	14.4B	15.3B	15.4B	10.6B

Short Long Term Debt Total Total Assets

Sequent Scientific balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Good Will	Accounts Payable	Short Term Investments	Intangible Assets	Current Deferred Revenue
Total Assets		0.66	0.25	0.83	0.93	0.68	0.57	0.72	0.95	0.62	0.85	0.89	0.96	0.8	0.66	0.48	0.84	0.87	0.93	0.96	0.57	0.91	0.81	0.53	0.69	0.57
Short Long Term Debt Total	0.66		-0.12	0.81	0.39	0.69	0.99	0.38	0.61	0.26	0.37	0.54	0.62	0.83	0.51	0.46	0.37	0.87	0.63	0.65	0.79	0.48	0.52	0.16	0.18	0.19
Other Current Liab	0.25	-0.12		0.3	0.22	0.24	-0.15	0.17	0.36	0.5	0.4	0.02	0.09	0.12	-0.13	0.4	0.2	0.26	0.09	0.06	0.15	0.04	0.03	0.4	0.4	0.63
Total Current Liabilities	0.83	0.81	0.3		0.61	0.59	0.74	0.67	0.73	0.57	0.59	0.75	0.8	0.73	0.64	0.55	0.57	0.97	0.84	0.79	0.88	0.57	0.78	0.21	0.59	0.5
Total Stockholder Equity	0.93	0.39	0.22	0.61		0.53	0.3	0.66	0.89	0.6	0.89	0.84	0.9	0.6	0.59	0.39	0.9	0.65	0.86	0.9	0.3	0.95	0.75	0.64	0.73	0.57
Property Plant And Equipment Net	0.68	0.69	0.24	0.59	0.53		0.69	0.25	0.74	0.11	0.54	0.46	0.58	0.81	0.35	0.45	0.47	0.7	0.53	0.6	0.4	0.55	0.39	0.53	0.08	0.34
Net Debt	0.57	0.99	-0.15	0.74	0.3	0.69		0.23	0.55	0.21	0.27	0.43	0.52	0.8	0.43	0.49	0.27	0.8	0.52	0.55	0.75	0.39	0.41	0.16	0.1	0.15
Cash	0.72	0.38	0.17	0.67	0.66	0.25	0.23		0.56	0.39	0.71	0.85	0.8	0.46	0.67	-0.03	0.67	0.65	0.82	0.78	0.51	0.66	0.81	0.07	0.53	0.28
Non Current Assets Total	0.95	0.61	0.36	0.73	0.89	0.74	0.55	0.56		0.68	0.87	0.72	0.86	0.84	0.44	0.59	0.82	0.81	0.77	0.86	0.47	0.86	0.6	0.71	0.62	0.64
Non Currrent Assets Other	0.62	0.26	0.5	0.57	0.6	0.11	0.21	0.39	0.68		0.56	0.41	0.52	0.41	0.18	0.63	0.54	0.55	0.48	0.49	0.39	0.48	0.36	0.43	0.82	0.74
Cash And Short Term Investments	0.85	0.37	0.4	0.59	0.89	0.54	0.27	0.71	0.87	0.56		0.7	0.78	0.62	0.4	0.37	0.88	0.63	0.73	0.78	0.33	0.83	0.6	0.76	0.61	0.6
Net Receivables	0.89	0.54	0.02	0.75	0.84	0.46	0.43	0.85	0.72	0.41	0.7		0.96	0.62	0.83	0.16	0.75	0.76	0.98	0.94	0.51	0.85	0.92	0.2	0.63	0.35
Common Stock Shares Outstanding	0.96	0.62	0.09	0.8	0.9	0.58	0.52	0.8	0.86	0.52	0.78	0.96		0.75	0.75	0.3	0.83	0.83	0.96	0.99	0.56	0.9	0.87	0.35	0.63	0.41
Non Current Liabilities Total	0.8	0.83	0.12	0.73	0.6	0.81	0.8	0.46	0.84	0.41	0.62	0.62	0.75		0.46	0.44	0.51	0.86	0.66	0.75	0.61	0.69	0.5	0.44	0.33	0.32
Inventory	0.66	0.51	-0.13	0.64	0.59	0.35	0.43	0.67	0.44	0.18	0.4	0.83	0.75	0.46		0.05	0.48	0.62	0.83	0.74	0.56	0.63	0.89	-0.09	0.51	0.02
Other Current Assets	0.48	0.46	0.4	0.55	0.39	0.45	0.49	-0.03	0.59	0.63	0.37	0.16	0.3	0.44	0.05		0.35	0.55	0.3	0.3	0.4	0.27	0.26	0.55	0.51	0.66
Other Stockholder Equity	0.84	0.37	0.2	0.57	0.9	0.47	0.27	0.67	0.82	0.54	0.88	0.75	0.83	0.51	0.48	0.35		0.58	0.76	0.85	0.25	0.84	0.65	0.61	0.56	0.52
Total Liab	0.87	0.87	0.26	0.97	0.65	0.7	0.8	0.65	0.81	0.55	0.63	0.76	0.83	0.86	0.62	0.55	0.58		0.83	0.83	0.85	0.64	0.74	0.3	0.54	0.47
Total Current Assets	0.93	0.63	0.09	0.84	0.86	0.53	0.52	0.82	0.77	0.48	0.73	0.98	0.96	0.66	0.83	0.3	0.76	0.83		0.95	0.61	0.85	0.94	0.28	0.69	0.42
Common Stock	0.96	0.65	0.06	0.79	0.9	0.6	0.55	0.78	0.86	0.49	0.78	0.94	0.99	0.75	0.74	0.3	0.85	0.83	0.95		0.57	0.92	0.86	0.38	0.6	0.36
Short Term Debt	0.57	0.79	0.15	0.88	0.3	0.4	0.75	0.51	0.47	0.39	0.33	0.51	0.56	0.61	0.56	0.4	0.25	0.85	0.61	0.57		0.32	0.61	-0.01	0.4	0.15
Good Will	0.91	0.48	0.04	0.57	0.95	0.55	0.39	0.66	0.86	0.48	0.83	0.85	0.9	0.69	0.63	0.27	0.84	0.64	0.85	0.92	0.32		0.72	0.56	0.63	0.36
Accounts Payable	0.81	0.52	0.03	0.78	0.75	0.39	0.41	0.81	0.6	0.36	0.6	0.92	0.87	0.5	0.89	0.26	0.65	0.74	0.94	0.86	0.61	0.72		0.09	0.66	0.27
Short Term Investments	0.53	0.16	0.4	0.21	0.64	0.53	0.16	0.07	0.71	0.43	0.76	0.2	0.35	0.44	-0.09	0.55	0.61	0.3	0.28	0.38	-0.01	0.56	0.09		0.37	0.61
Intangible Assets	0.69	0.18	0.4	0.59	0.73	0.08	0.1	0.53	0.62	0.82	0.61	0.63	0.63	0.33	0.51	0.51	0.56	0.54	0.69	0.6	0.4	0.63	0.66	0.37		0.59
Current Deferred Revenue	0.57	0.19	0.63	0.5	0.57	0.34	0.15	0.28	0.64	0.74	0.6	0.35	0.41	0.32	0.02	0.66	0.52	0.47	0.42	0.36	0.15	0.36	0.27	0.61	0.59

Click cells to compare fundamentals

Sequent Scientific Account Relationship Matchups

Sequent Scientific balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.2B	13.9B	14.4B	15.3B	15.4B	10.6B
Short Long Term Debt Total	3.9B	2.8B	3.6B	4.4B	4.9B	3.1B
Other Current Liab	474.9M	734.6M	418.9M	134.1M	393.8M	610.9M
Total Current Liabilities	4.7B	4.6B	5.1B	5.3B	6.3B	3.8B
Total Stockholder Equity	7.4B	7.3B	6.9B	7.0B	6.6B	4.5B
Property Plant And Equipment Net	3.6B	3.5B	3.3B	3.5B	3.1B	2.9B
Net Debt	3.2B	2.2B	3.1B	4.0B	4.2B	2.8B
Cash	681.0M	537.4M	575.0M	415.7M	648.1M	354.1M
Non Current Assets Total	8.1B	6.8B	6.5B	7.4B	7.2B	5.9B
Non Currrent Assets Other	140.1M	150.8M	222.1M	332.8M	312.9M	269.9M
Cash And Short Term Investments	1.1B	597.0M	591.2M	428.8M	687.9M	477.7M
Net Receivables	3.2B	3.5B	3.3B	3.4B	3.4B	2.0B
Common Stock Shares Outstanding	245.3M	247.9M	250.7M	250.1M	249.1M	185.4M
Liabilities And Stockholders Equity	15.2B	13.9B	14.4B	15.3B	15.4B	10.6B
Non Current Liabilities Total	2.6B	1.6B	1.9B	2.5B	2.0B	2.0B
Inventory	2.2B	2.6B	3.5B	3.5B	3.5B	3.6B
Other Current Assets	576.8M	436.9M	470.3M	612.2M	735.7M	616.3M
Other Stockholder Equity	8.4B	8.6B	8.7B	2.0B	8.7B	4.9B
Total Liab	7.3B	6.2B	7.0B	7.8B	8.3B	5.7B
Total Current Assets	7.0B	7.1B	7.9B	7.9B	8.2B	4.7B
Accumulated Other Comprehensive Income	(1.4B)	(2.5B)	(3.1B)	(3.5B)	(3.9B)	(3.7B)
Short Term Debt	2.0B	1.4B	2.0B	2.6B	3.2B	2.0B
Good Will	2.4B	1.7B	1.9B	2.4B	2.3B	1.5B
Accounts Payable	2.2B	2.3B	2.6B	2.4B	2.6B	1.9B
Short Term Investments	401.8M	59.6M	16.3M	13.1M	39.8M	37.8M
Intangible Assets	517.0M	443.9M	559.5M	684.2M	617.2M	535.8M
Current Deferred Revenue	510.2M	812.5M	397.2M	338.4M	81.3M	77.2M
Retained Earnings	(791.2M)	599.7M	888.9M	996.9M	1.2B	1.3B
Other Liab	543.4M	326.2M	162.4M	246.5M	221.9M	378.6M
Net Tangible Assets	4.5B	5.1B	4.5B	3.9B	4.5B	4.5B
Other Assets	372.3M	355.9M	514.1M	502.9M	(1.0)	(0.95)
Long Term Debt	1.5B	937.1M	1.2B	1.8B	1.4B	1.3B
Short Long Term Debt	1.8B	1.0B	1.9B	2.2B	3.1B	2.1B
Property Plant Equipment	3.6B	3.5B	3.3B	3.5B	3.2B	2.7B
Long Term Debt Total	2.0B	1.4B	1.2B	2.2B	2.0B	1.3B
Capital Surpluse	8.6B	8.7B	8.7B	9.0B	8.1B	7.2B
Capital Lease Obligations	607.2M	522.9M	500.1M	457.0M	364.1M	354.1M
Non Current Liabilities Other	13.1M	8.7M	6.8M	3.7M	3.3M	3.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Sequent Stock Analysis

When running Sequent Scientific's price analysis, check to measure Sequent Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sequent Scientific is operating at the current time. Most of Sequent Scientific's value examination focuses on studying past and present price action to predict the probability of Sequent Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sequent Scientific's price. Additionally, you may evaluate how the addition of Sequent Scientific to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC